Ken Griffin Catalyst Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$15.19 - $21.35 $10,633 - $14,945	-700 Reduced 8.33%	7,700 $153,000
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $44,040 - $50,760	-3,000 Reduced 26.32%	8,400 $130,000
Q1 2024 May 15, 2024	SELL	$13.18 - $17.11 $322,910 - $419,195	-24,500 Reduced 68.25%	11,400 $181,000
Q4 2023 Feb 14, 2024	BUY	$11.78 - $17.29 $259,160 - $380,380	22,000 Added 158.27%	35,900 $603,000
Q3 2023 Nov 14, 2023	SELL	$11.69 - $15.02 $403,305 - $518,190	-34,500 Reduced 71.28%	13,900 $162,000
Q2 2023 Aug 14, 2023	SELL	$11.5 - $18.08 $195,500 - $307,360	-17,000 Reduced 25.99%	48,400 $650,000
Q1 2023 May 15, 2023	BUY	$14.34 - $21.05 $573,600 - $842,000	40,000 Added 157.48%	65,400 $1.08 Million
Q4 2022 Feb 14, 2023	SELL	$12.25 - $19.5 $193,550 - $308,100	-15,800 Reduced 38.35%	25,400 $472,000
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $168,734 - $370,928	23,900 Added 138.15%	41,200 $529,000

327

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.3B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.